Metastatic Breast Cancer to the Spine: Incidence of Somatic Gene Alterations and Association of Targeted Therapies With Overall Survival

Author:

Rabah Nicholas M.12ORCID,Jarmula Jakub23,Hamza Omar24,Khan Hammad A.5,Chakravarthy Vikram6,Habboub Ghaith2,Wright James M.7,Steinmetz Michael P.23,Wright Christina H.7,Krishnaney Ajit A.23

Affiliation:

1. Department of Neurosurgery, Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix, Arizona, USA;

2. Cleveland Clinic Center for Spine Health, Neurologic Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA;

3. Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio, USA;

4. Case Western Reserve University School of Medicine, Cleveland, Ohio, USA;

5. Department of Neurosurgery, New York University, New York, New York, USA;

6. Department of Neurosurgery, Memorial Sloan Kettering, New York, New York, USA;

7. Department of Neurosurgery, Oregon Health & Science University, Portland, Oregon, USA

Abstract

BACKGROUND: The increase in use of targeted systemic therapies in cancer treatments has catalyzed the importance of identifying patient- and tumor-specific somatic mutations, especially regarding metastatic disease. Mutations found to be most prevalent in patients with metastatic breast cancer include TP53, PI3K, and CDH1. OBJECTIVE: To determine the incidence of somatic mutations in patients with metastatic breast cancer to the spine (MBCS). To determine if a difference exists in overall survival (OS), progression-free survival, and progression of motor symptoms between patients who do or do not undergo targeted systemic therapy after treatment for MBCS. METHODS: This is a retrospective study of patients with MBCS. Review of gene sequencing reports was conducted to calculate the prevalence of various somatic gene mutations within this population. Those patients who then underwent treatment (surgery/radiation) for their diagnosis of MBCS between 2010 and 2020 were subcategorized. The use of targeted systemic therapy in the post-treatment period was identified, and post-treatment OS, progression-free survival, and progression of motor deficits were calculated for this subpopulation. RESULTS: A total of 131 patients were included in the final analysis with 56% of patients found to have a PI3K mutation. Patients who received targeted systemic therapies were found to have a significantly longer OS compared with those who did not receive targeted systemic therapies. CONCLUSION: The results of this study demonstrate that there is an increased prevalence of PI3K mutations in patients with MBCS and there are a significant survival benefit and delay in progression of motor symptoms associated with using targeted systemic therapies for adjuvant treatment.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Neurology (clinical),Surgery

Reference41 articles.

1. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung;CA: A Cancer J Clin.,2021

2. Current trends in incidence, characteristics, and surgical management of metastatic breast cancer to the spine: a National Inpatient Sample analysis from 2005 to 2014;Peterson;J Clin Neurosci.,2021

3. Breast cancer survivorship, quality of life, and late toxicities;Nardin;Front Oncol.,2020

4. Diagnosis and management of metastatic spine disease. A review;Sciubba;J Neurosurg Spine.,2010

5. Malignant spinal-cord compression;Prasad;Lancet Oncol.,2005

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3